JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB238617

Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin)

Be the first to review this product! Submit a review

|

(2 Publications)

Suitable for IHC-P, sELISA, WB. Cited in 2 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4

5 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)

Paraffin-embedded human lymphoid tissue stained for IgG4 heavy chain using ab238617 at 10 μg/mL in immunohistochemical analysis.

ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)
  • ELISA

Supplier Data

ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)

A titer ELISA using ab238617. The plate was coated with different amounts of human IgG4. A serial dilution of ab238617 was used as the primary antibody. An alkaline phosphatase conjugated anti-rabbit IgG was used as the secondary antibody.``

Sandwich ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)
  • sELISA

Supplier Data

Sandwich ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)

Sandwich ELISA using ab238617 as the capture antibody, and a biotinylated anti-human light chains ( κ+ λ) antibody as the detection antibody, followed by an AP conjugated streptavidin.``

Sandwich ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)
  • sELISA

Supplier Data

Sandwich ELISA - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)

Sandwich ELISA using ab238617 as the capture antibody at 200ng/well, and a Biotinylated anti-human light chains (κ+ λ) antibody as the detection antibody, followed by an AP conjugated streptavidin.``

Western blot - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)
  • WB

Supplier Data

Western blot - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (AB238617)

Western Blot of human, mouse, rat, and goat IgG shows RM120 reacts to human IgG4, in both whole molecule (~150kDa, non-reduced) and heavy chain (~50kDa, reduced) forms (Lane 4). No cross reactivity with other isotypes of human IgG, or mouse, rat, or goat IgG.

Lane 1:

Non-reduced (-) and reduced (+) forms of Human IgG1

Lane 2:

Non-reduced (-) and reduced (+) forms of Human IgG2

Lane 3:

Non-reduced (-) and reduced (+) forms of Human IgG3

Lane 4:

Non-reduced (-) and reduced (+) forms of Human IgG4

Lane 5:

Non-reduced (-) and reduced (+) forms of Mouse IgG

Lane 6:

Non-reduced (-) and reduced (+) forms of Rat IgG

Lane 7:

Non-reduced (-) and reduced (+) forms of Goat IgG

Secondary

All lanes:

Western blot - Rabbit monoclonal [RM120] Anti-Human IgG4 heavy chain (Biotin) (ab238617) at 2 µg/mL

false

Key facts

Host species

Rabbit

Target species

Human

Target isotype

IgG4

Target specificity

Heavy chain

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

Biotin

Excitation/Emission
Applications

IHC-P, sELISA, WB

applications

Clonality

Monoclonal

Clone number

RM120

Isotype

IgG

Immunogen

Synthetic Peptide within Human IGHG4. The exact immunogen used to generate this antibody is proprietary information.

P01861

Specificity

ab238617 reacts to the heavy chain of human IgG4. No cross reactivity with human IgG1, IgG2, IgG3, IgM, IgA, IgD, IgE, mouse IgG, rat IgG, or goat IgG.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "IHC-P": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1-10 µg/mL", "notes":"<p></p>" }, "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Use 50ng/well – 200ng/well (for Capture); 0.05μg/mL – 0.2μg/mL (for Detection).</p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"0.5-2 µg/mL", "notes":"<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Purification notes
Purified from an animal origin–free culture supernatant.
Storage buffer
Preservative: 0.09% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region interacts (via the fragment crystallizable, Fc) with the Fc receptors on innate immune cells to mediate humoral effector functions. Ig gamma-4 (IgG4) isotype does not elicit antibody-dependent cellular cytotoxicity (ADDC) or complement-dependent cytotoxicity (CDC). Instead it is likely involved in immune tolerance mechanisms to allergens and parasites either by blocking IgE-antigen complex formation or by directly inhibiting mast cell degranulation through Fc receptor signaling. In the context of tumorigenesis, it may participate in immunosuppressive mechanisms.
See full target information IGHG4

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Advanced materials (Deerfield Beach, Fla.) 36:e2402570 PubMed38678378

2024

Catheter-Directed Ionic Liquid Embolic Agent for Rapid Portal Vein Embolization, Segmentectomy, and Bile Duct Ablation.

Applications

Unspecified application

Species

Unspecified reactive species

Enes Cevik,Hassan Albadawi,Zefu Zhang,Yusuf Demirlenk,Dila Atar,Chris Keum,Jinjoo Kim,Erin Graf,Seyda Gunduz,Suliman Rehman,Rahmi Oklu

Advanced materials (Deerfield Beach, Fla.) 36:e2309412 PubMed38305472

2024

Bioengineered Ionic Liquid for Catheter-Directed Tissue Ablation, Drug Delivery, and Embolization.

Applications

Unspecified application

Species

Unspecified reactive species

Hyeongseop Keum,Hassan Albadawi,Zefu Zhang,Erin Graf,Pedro Reck Dos Santos,Seyda Gunduz,Rahmi Oklu
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com